KR101736502B1 - Ｇｌｐ-1에 의한 유해 효과의 예방 방법 - Google Patents

Ｇｌｐ-1에 의한 유해 효과의 예방 방법 Download PDF

Info

Publication number
KR101736502B1
KR101736502B1 KR1020107011096A KR20107011096A KR101736502B1 KR 101736502 B1 KR101736502 B1 KR 101736502B1 KR 1020107011096 A KR1020107011096 A KR 1020107011096A KR 20107011096 A KR20107011096 A KR 20107011096A KR 101736502 B1 KR101736502 B1 KR 101736502B1
Authority
KR
South Korea
Prior art keywords
glp
dry powder
formulation
administration
fdkp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107011096A
Other languages
English (en)
Korean (ko)
Other versions
KR20100093055A (ko
Inventor
피터 리챠드슨
로버트 에이 보프만
도날드 코스텔로
Original Assignee
맨카인드 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 맨카인드 코포레이션 filed Critical 맨카인드 코포레이션
Publication of KR20100093055A publication Critical patent/KR20100093055A/ko
Application granted granted Critical
Publication of KR101736502B1 publication Critical patent/KR101736502B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107011096A 2007-10-24 2008-10-24 Ｇｌｐ-1에 의한 유해 효과의 예방 방법 Expired - Fee Related KR101736502B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US98236807P 2007-10-24 2007-10-24
US60/982,368 2007-10-24
US98562007P 2007-11-05 2007-11-05
US60/985,620 2007-11-05
US3374008P 2008-03-04 2008-03-04
US61/033,740 2008-03-04
US5212708P 2008-05-09 2008-05-09
US61/052,127 2008-05-09
PCT/US2008/081218 WO2009055740A2 (en) 2007-10-24 2008-10-24 Method of preventing adverse effects by glp-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137027725A Division KR101736535B1 (ko) 2007-10-24 2008-10-24 Ｇｌｐ-1에 의한 유해 효과의 예방 방법

Publications (2)

Publication Number Publication Date
KR20100093055A KR20100093055A (ko) 2010-08-24
KR101736502B1 true KR101736502B1 (ko) 2017-05-16

Family

ID=40546046

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107011096A Expired - Fee Related KR101736502B1 (ko) 2007-10-24 2008-10-24 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
KR1020137027725A Expired - Fee Related KR101736535B1 (ko) 2007-10-24 2008-10-24 Ｇｌｐ-1에 의한 유해 효과의 예방 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137027725A Expired - Fee Related KR101736535B1 (ko) 2007-10-24 2008-10-24 Ｇｌｐ-1에 의한 유해 효과의 예방 방법

Country Status (15)

Country Link
US (4) US8377869B2 (cg-RX-API-DMAC7.html)
EP (2) EP2954893A1 (cg-RX-API-DMAC7.html)
JP (2) JP2011500850A (cg-RX-API-DMAC7.html)
KR (2) KR101736502B1 (cg-RX-API-DMAC7.html)
CN (1) CN101969927A (cg-RX-API-DMAC7.html)
AU (2) AU2008316634B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818872A2 (cg-RX-API-DMAC7.html)
CA (1) CA2703338A1 (cg-RX-API-DMAC7.html)
DK (1) DK2211842T3 (cg-RX-API-DMAC7.html)
ES (1) ES2547529T3 (cg-RX-API-DMAC7.html)
HU (1) HUE025485T2 (cg-RX-API-DMAC7.html)
MX (1) MX2010004510A (cg-RX-API-DMAC7.html)
PL (1) PL2211842T3 (cg-RX-API-DMAC7.html)
RU (2) RU2474415C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009055740A2 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2377204C (en) 1999-06-29 2015-01-20 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
IN2014DN09128A (cg-RX-API-DMAC7.html) 2005-09-14 2015-07-10 Mannkind Corp
CN101389348A (zh) 2006-02-22 2009-03-18 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US8785396B2 (en) * 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
HUE025485T2 (en) 2007-10-24 2016-02-29 Mannkind Corp Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
CN103908712A (zh) * 2008-03-27 2014-07-09 曼金德公司 干燥粉末吸入系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN109568740B (zh) 2008-06-13 2022-05-27 曼金德公司 干粉吸入器和用于药物输送的系统
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
BR122020002400B1 (pt) 2008-06-20 2021-12-07 Mannkind Corporation Sistema de detecção de inalação de pó seco e sistema de monitoramento acoplável para um inalador de pó seco
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5918539B2 (ja) * 2009-01-08 2016-05-18 マンカインド コーポレイション Ｇｌｐ−１を用いる高血糖症の治療方法
KR101733816B1 (ko) * 2009-03-04 2017-05-08 맨카인드 코포레이션 개선된 건조 분말 약물 전달 시스템
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
ES2880102T3 (es) * 2009-06-12 2021-11-23 Mannkind Corp Micropartículas de dicetopiperazina con contenido de isómeros definido
CA2764505C (en) * 2009-06-12 2018-09-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011017554A2 (en) * 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
KR101907699B1 (ko) * 2009-11-02 2018-10-12 맨카인드 코포레이션 침전 프로세스에서 약제학적 입자를 제조하기 위한 반응기
JP5960599B2 (ja) 2009-11-02 2016-08-02 マンカインド コーポレ−ション 医薬組成物を造粒するための装置および方法
AU2015203301B2 (en) * 2009-11-02 2017-05-25 Mannkind Corporation Reactor for producing pharmaceutical particles in a precipitation process
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
JP6092113B2 (ja) * 2010-11-09 2017-03-08 マンカインド コーポレイション セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
CA2878457C (en) * 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
JP2015526523A (ja) * 2012-08-29 2015-09-10 マンカインド コーポレイション 高血糖症の治療のための方法および組成物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
RS57531B1 (sr) 2012-12-21 2018-10-31 Sanofi Sa Derivati eksendina-4 kao dualni glp1/gip- ili trigonalni glp1/gip/glukagon agonisti
MX392016B (es) 2013-03-15 2025-03-21 Mannkind Corp Composiciones de dicetopiperazina microcristalina y métodos.
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR102891823B1 (ko) 2023-06-30 2025-12-01 주식회사 휴온스랩 GLP (Glucagon Like Peptide) 유사체를 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물
WO2025220834A1 (ko) * 2024-04-16 2025-10-23 한미약품 주식회사 흡입제 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503420A (ja) * 1999-06-29 2003-01-28 ファーマシューティカル ディスカバリー コーポレイション ペプチドおよびタンパク質の薬学的因子の精製および安定化
WO2007033316A2 (en) * 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6645504B1 (en) * 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
FI972313A7 (fi) 1994-12-01 1997-07-30 Toyama Chemical Co Ltd Uusia 2,3-diketopiperatsiinijohdannaisia ja niiden suoloja
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
JP3098401B2 (ja) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
US6852690B1 (en) * 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
KR100568436B1 (ko) * 1996-02-27 2007-04-25 데이진 가부시키가이샤 분말상경비투여조성물
JPH1053765A (ja) * 1996-06-04 1998-02-24 Denso Corp スメクチック液晶組成物及び液晶セル
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
JP3020141B2 (ja) * 1996-10-07 2000-03-15 株式会社富士薬品 経鼻投与用製剤
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU4863797A (en) * 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
JP2002510193A (ja) * 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
WO1999029336A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE9802080D0 (sv) * 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
CA2307607C (en) * 1998-08-26 2008-02-05 Teijin Limited Powdery nasal compositions
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
CO5090908A1 (es) * 1998-08-28 2001-10-30 Lilly Co Eli Procedimiento para administrar peptidos insulinotropicos
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6440463B1 (en) 1999-04-05 2002-08-27 Pharmaceutical Discovery Corporation Methods for fine powder formation
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
PT1133312E (pt) * 1999-06-21 2007-11-30 Lilly Co Eli Uso sinergístico de tiazolidinodionas com péptido 1 semelhante ao glucagon e os seus agonistas para tratar diabetes não insulino-dependente
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
JP2003519664A (ja) * 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１誘導体の経上皮送達
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6608038B2 (en) * 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
US6447750B1 (en) * 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
ES2275685T3 (es) * 2000-06-16 2007-06-16 Eli Lilly And Company Analogos del peptido similar a glucagon 1.
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2001268958B2 (en) * 2000-07-04 2006-03-09 Novo Nordisk A/S Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
MXPA03005135A (es) * 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
DE60209343T2 (de) * 2001-04-11 2006-10-26 Bristol-Myers Squibb Co. Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
US7232897B2 (en) * 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
AU2002308706A1 (en) * 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
AU2002322403A1 (en) * 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7238663B2 (en) * 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
EP1448222A4 (en) * 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
US20040121964A1 (en) * 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP1698329A4 (en) * 2003-12-24 2009-10-28 Ltt Bio Pharma Co Ltd PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES
JP2007536268A (ja) * 2004-05-06 2007-12-13 エミスフェアー・テクノロジーズ・インク 固体剤形の湿性ヘパリン
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
WO2006023944A2 (en) 2004-08-23 2006-03-02 Mannkind Corporation Pulmonary delivery of inhibitors of phosphodiesterase type 5
SE0402976L (sv) * 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
CA2589118A1 (en) * 2004-12-03 2006-06-08 Mederio Ag A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
US20060153778A1 (en) * 2005-01-10 2006-07-13 Mannkind Corporation Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2007030706A1 (en) 2005-09-08 2007-03-15 New England Medical Center Hospitals, Inc. Fragments of the glucagon-like peptide-i and uses thereof
JP5096363B2 (ja) * 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
CN101389348A (zh) * 2006-02-22 2009-03-18 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
KR20150042304A (ko) * 2006-04-14 2015-04-20 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
US8454971B2 (en) * 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AU2008316636B2 (en) * 2007-10-24 2014-02-06 Mannkind Corporation Delivery of active agents
HUE025485T2 (en) 2007-10-24 2016-02-29 Mannkind Corp Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
EP2060268A1 (en) 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
JP5918539B2 (ja) * 2009-01-08 2016-05-18 マンカインド コーポレイション Ｇｌｐ−１を用いる高血糖症の治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503420A (ja) * 1999-06-29 2003-01-28 ファーマシューティカル ディスカバリー コーポレイション ペプチドおよびタンパク質の薬学的因子の精製および安定化
WO2007033316A2 (en) * 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces

Also Published As

Publication number Publication date
RU2474415C2 (ru) 2013-02-10
US20220387593A1 (en) 2022-12-08
JP2015013892A (ja) 2015-01-22
AU2014202731A1 (en) 2014-06-12
AU2008316634A1 (en) 2009-04-30
HUE025485T2 (en) 2016-02-29
KR101736535B1 (ko) 2017-05-16
US20130125886A1 (en) 2013-05-23
KR20130123467A (ko) 2013-11-12
CN101969927A (zh) 2011-02-09
RU2010120666A (ru) 2011-11-27
KR20100093055A (ko) 2010-08-24
US20200147219A1 (en) 2020-05-14
EP2211842B1 (en) 2015-08-12
DK2211842T3 (en) 2015-09-21
BRPI0818872A2 (pt) 2015-05-05
MX2010004510A (es) 2010-07-02
CA2703338A1 (en) 2009-04-30
JP2011500850A (ja) 2011-01-06
ES2547529T3 (es) 2015-10-07
US20090110647A1 (en) 2009-04-30
EP2211842A2 (en) 2010-08-04
PL2211842T3 (pl) 2015-12-31
EP2954893A1 (en) 2015-12-16
WO2009055740A3 (en) 2009-06-11
AU2008316634B2 (en) 2014-02-27
WO2009055740A2 (en) 2009-04-30
RU2012146344A (ru) 2014-05-10
US8377869B2 (en) 2013-02-19

Similar Documents

Publication Publication Date Title
KR101736502B1 (ko) Ｇｌｐ-1에 의한 유해 효과의 예방 방법
EP2379100B1 (en) Treating hyperglycemia with glp-1
JP5813323B2 (ja) 活性薬剤の送達方法
US8921311B2 (en) Method for treating hyperglycemia
US20170304404A1 (en) Method for treating hyperglycemia with glp-1
US11304992B2 (en) Inhalable dry powder pharmaceutical composition
US20230293436A1 (en) Inhalable dry powder pharmaceutical composition
HK1164112B (en) Treating hyperglycemia with glp-1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A107 Divisional application of patent
A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

J301 Trial decision

Free format text: TRIAL NUMBER: 2015101005638; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150925

Effective date: 20170125

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20170125

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2010 7011096

Appeal request date: 20150925

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015101005638

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210511

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210511

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000